Auris raises $50.5m for inner ear drugs
This article was originally published in Scrip
Executive Summary
Swiss inner ear therapeutics developer Auris Medical, which has a US office in Chicago, raised CHF 47.1 million ($50.5 million) in a Series C venture funding round to take its tinnitus and hearing loss drugs into Phase III clinical trials and finance commercial activities.